Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...
The Brighterside of News on MSN
Experimental drug can sharply reduce amyloid beta's impact on Alzheimer’s
Early in Alzheimer’s disease, your brain can begin to change long before anyone notices a lost name or missed appointment.
Richard Silverman, PhD, is a Northwestern University chemist whose name bears the building. His experimentation led to the ...
A new drug candidate shows promise by reversing cognitive decline in advanced Alzheimer's disease by restoring brain balance ...
Investing.com -- Biogen Inc. ’s new at-home Alzheimer’s drug will provide an advantage over Eli Lilly Co. ’s competing ...
Morning Overview on MSN
SciNeuro, Novartis strike $1.7B Alzheimer’s drug megadeal
Novartis has agreed to pay up to $1.7 billion to license an experimental Alzheimer’s therapy from China-based SciNeuro, a ...
Swiss drugmaker Novartis has signed a licensing deal worth nearly $1.7 billion with privately held SciNeuro Pharmaceuticals ...
Potentially more than 90% of Alzheimer's disease cases would not occur without the contribution of a single gene (APOE), ...
Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...
Men's Health debunks common nicotine health hacks, from improving cognition to boosting T levels to protecting us from ...
An experimental Alzheimer's disease drug from Eisai (4523.T) and Biogen (BIIB.O) slowed cognitive decline in a closely watched trial but may carry a risk of dangerous side effects for certain patients ...
Johns Hopkins researchers identified a new target for treating Alzheimer’s disease by focusing on a protein that produces tiny amounts of hydrogen sulfide in healthy brain cells.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback